Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23816573 | 0.95 | BTK (0.38) | BTKCRBNDDB1LCKJAK2 | |
| SCHEMBL23816018 | 0.94 | BTK (0.39) | BTKCRBNDDB1LCKGSPT1 | |
| SCHEMBL26517883 | 0.94 | BTK (0.39) | BTKCRBNDDB1LCKGSPT1 | |
| SCHEMBL23816174 | 0.94 | BTK (0.38) | BTKCRBNDDB1LCKJAK2 | |
| SCHEMBL26111571 | 0.94 | BTK (0.39) | BTKCRBNDDB1LCKJAK2 | |
| SCHEMBL23803784 | 0.94 | BTK (0.39) | BTKCRBNDDB1LCKJAK2 | |
| SCHEMBL23803728 | 0.94 | BTK (0.39) | BTKCRBNDDB1LCKJAK2 | |
| SCHEMBL26116027 | 0.92 | BTK (0.37) | BTKCRBNDDB1LCKGSPT1 | |
| SCHEMBL23816077 | 0.91 | BTK (0.38) | BTKCRBNDDB1LCKJAK2 | |
| SCHEMBL23816191 | 0.90 | BTK (0.40) | BTKCRBNDDB1LCKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| CN-115335376-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitor with E3 ligase ligand and methods of use thereof | 百济神州有限公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021180103-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | BTK 1/4885CRBN 84/4885DDB1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.